• to copy, distribute, display, and perform the work.• to make derivative works.
Under the following conditions:• Attribution -You must give the original author credit.• Non-Commercial -You may not use this work for commercial purposes.• suggest the benefit of introducing an initial high treatment of TGF-β 1 (10ng/ml) followed by a low continuous treatment (0.2ng/ml) to enhance human osteogenesis on the scaffold. Osteogenesis coincided with a reduction in scaffold size and shape (up to 70% that of original). A notable finding was that after 49 days of culture, core degradation was identified at the centre of the tissue engineered construct. This was not observed at earlier time points therefore a maximum of 35 days in culture to be an appropriate end point for in vitro studies of these scaffolds. Weconclude that the CG scaffold shows excellent potential as a biomaterial for human bone tissue engineering.